Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Non-Current Assets (2021 - 2025)

Verrica Pharmaceuticals has reported Non-Current Assets over the past 5 years, most recently at $4.6 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $4.6 million for Q4 2025, up 55.4% from a year ago — trailing twelve months through Dec 2025 was $14.2 million (down 17.76% YoY), and the annual figure for FY2025 was $4.6 million, up 55.4%.
  • Non-Current Assets for Q4 2025 was $4.6 million at Verrica Pharmaceuticals, down from $4.6 million in the prior quarter.
  • Over the last five years, Non-Current Assets for VRCA hit a ceiling of $6.1 million in Q2 2022 and a floor of $2.3 million in Q2 2025.
  • Median Non-Current Assets over the past 5 years was $5.4 million (2023), compared with a mean of $4.9 million.
  • Peak annual rise in Non-Current Assets hit 55.4% in 2025, while the deepest fall reached 50.43% in 2025.
  • Verrica Pharmaceuticals' Non-Current Assets stood at $5.8 million in 2021, then decreased by 3.29% to $5.6 million in 2022, then fell by 27.45% to $4.1 million in 2023, then dropped by 27.34% to $3.0 million in 2024, then skyrocketed by 55.4% to $4.6 million in 2025.
  • The last three reported values for Non-Current Assets were $4.6 million (Q4 2025), $4.6 million (Q3 2025), and $2.3 million (Q2 2025) per Business Quant data.